SCHEMBL14031990

SCHEMBL14031990

CN(C)CC(=O)N1CCC(Cc2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)cccn23)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 17/20 0.46
CYP3A4 P08684 9/20 0.46
TNK2 Q07912 1/20 0.42
INSR P06213 4/20 0.41
KDR P35968 2/20 0.41
MAPK3 P27361 2/20 0.41
MAPK1 P28482 2/20 0.41
RIPK2 O43353 1/20 0.41
ROCK2 O75116 1/20 0.41
LATS1 O95835 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
ABCB1 P08183 1/20 0.41
MET P08581 1/20 0.41
FGFR1 P11362 1/20 0.41
INSRR P14616 1/20 0.41
FECH P22830 1/20 0.41
MARK3 P27448 1/20 0.41
FLT4 P35916 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14031987 0.91 IGF1R (0.46) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031642 0.91 IGF1R (0.44) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031649 0.90 IGF1R (0.42) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL401368 0.89 IGF1R (0.59) IGF1RCYP3A4TNK2INSRKDR
SCHEMBL14031798 0.88 TNK2 (0.56) IGF1RCYP3A4TNK2INSRKDR
SCHEMBL14031809 0.87 IGF1R (0.44) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031647 0.85 GRIN2B (0.45) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031806 0.85 IGF1R (0.46) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031991 0.82 IGF1R (0.47) IGF1RCYP3A4INSRKDRMAPK3
SCHEMBL14031988 0.82 IGF1R (0.44) IGF1RCYP3A4INSRKDRMAPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 US disclosed
US-20080267957-A1 Combination cancer therapy OSI PHARMACEUTICALS, INC. 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080267957-A1 Combination cancer therapy IGF1R, IGFBP4, IGFBP1 IGF1R 1/4885CYP3A4 1844/4885TNK2 1029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.